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Introduction
Glioblastoma, which is the most common and most
malignant primary brain tumor in adults, presents
a supreme challenge to the local modes of therapy. There
is abundant evidence that it cannot be eradicated by the
presently available surgical and radiotherapeutical
techniques. Thus, we believe that treatment of this tumor
should be as simple, short and devoid of side effects as
possible.
Gliƒski reported a randomized study of 108 patients
comparing 50 Gy in 25 fractions to the whole brain to
a hypofractionated regimen consisting of three courses
of irradiation separated by 1-month intervals. The first
two courses of hypofractionated radiation consisted of
20 Gy in 5 fractions to the whole brain, while the third
course was a 10 Gy boost to the tumor in 5 fractions. An
analysis of all 108 randomized patients demonstrated no
significant difference in survival between the treatment
arms, but there was a significant survival benefit favoring
hypofractionated radiation, as compared with con-
ventional radiation in the subgroup of 44 patients with
glioblastoma (23% vs. 10% at 2 years at p level = 0.05)
[1].
In an attempt to increase the effective biolologic
dose to the tumor and to improve local control, twice-a-
day accelerated irradiation has been used in our
institution. Patients were treated with 2.65 Gy per
fraction, twice daily with 6 hour interval between fractions
up to the total dose of 53 Gy over 12 days. Survival rate at
2 years was 15% [2, 3].
The objective of this study is to evaluate and
compare the efficacy of postoperative hypofractionated
schedules of irradiation in two randomized groups of
adult patients with glioblastoma.
Material and methods
The studied population was derived from neurosurgical centers
which referred patients to the Maria Sklodowska-Curie Me-
morial Cancer Center in Kraków for radiation therapy. The
study began in January 1994. Through December 2002, 118
patients were accrued. The eligibility criteria for the trial were as
follows:
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– Pathologically confirmed supratentorial glioblastoma (surgery
consisted of as complete a excision as was deemed feasible; all
surgical specimens were evaluated by the same pathologist)
– Patient age between 18 and 65
– No previous definitive treatment of brain tumor
– Neurological performance status (NPS) good enough to render
radiotherapy possible (1-3 pts acc. to the EORTC/MRC scale)
[4].
– Karnofsky’s performance status (KPS) of 60 and more [5].
Informed consent was obtained before enrollment, acc. to
the rules of the Hospital Ethics Committee. Eligible patients
were randomized without stratification, using a table of random
numbers, to one of the two treatment arms: ITW (interval of two
weeks) or IFW (interval of four weeks).
Radiotherapy was started 3-7 weeks after surgery (median
time: 38 days). External beam radiotherapy was used with
a Cobalt-60 unit or linear accelerator with 6-8 MeV photons,
in the supine position. All patients were immobilized with
thermoplastic masks. Computerized planning of dose
distribution was performed with CT based planning. The dose
was specified and normalized at the treatment isocenter with
the 95% isodose encompassing the target volume. The PTV
(planning target volume) encompassed the tumor bed and
oedema with a margin of 2 cm. There were three irradiation
courses separated by 2 week (ITW) or 4 week intervals (IFW). In
both arms, the patients received 20 Gy in five fractions in five
days (from Monday to Friday). If the patients’ general or
neurological condition deteriorated in-between the courses,
supportive care only was given, but these patients were
considered evaluable and were not excluded from the statistical
analysis.
NPS and Karnofsky’s performance status of each patient
were carefully recorded before the onset of radiotherapy,
immediately after the termination of treatment and at each
follow-up examination.
The distribution of patient characteristics by treatment
schedule (ITW vs. IFW) has been presented in Tables I and II.
S u p p o r t i v e  t r e a t m e n t
Systemic anticonvulsants were administered to all patients during
irradiation. Dexamethasone was given in a dose of 12-24 mg/day,
only as symptomatic medication required for the control of
cerebral edema.
Fo l l o w - u p
Patients were followed-up every 4 months after treatment
completion. Physical and neurological examinations were
performed at each follow-up visit. A CT scan of the brain was
obtained when clinically indicated.
S t a t i s t i c a l  m e t h o d s
At the time of this analysis, 116 of 118 patients were known to be
dead. Overall survival (OS) analysis was performed using the
Kaplan-Meier method for uinivariate variable testing with log-
rank statistics, while Cox’s proportional hazard modeling was
used for multivariate testing [6, 7]. In all statistical procedures,
p values below 0.05 were considered significant. Survival was
measured from the date of first irradiation until death or date of
last follow-up. The following factors were studied for the
prognostic significance for OS: sex, age, KPS and NPS status,
tumor location, extent of tumor resection, time between surgery
and the first course of irradiation, and technique of irradiation
(number of fields).
Results
To l e r a n c e  t o  t h e  t r e a t m e n t
Irradiation was generally well tolerated in both groups.
Skin reactions in the ITW group were not reported to
be more severe than those of IFW regimen. Signs and
symptoms of increased intracranial pressure occurred in
three patients (5%) from the ITW group and in four
patients (7%) from the IFW group.
Three patients from the ITW arm and five patients
in IFW arm did not complete planned treatment because
of disease progression.
S u r v i v a l
The Kaplan-Meier survival curves calculated according to
the treatment option are presented in Figure 1.
No significant difference was observed between the
IFW and ITW regimens, with a two year OS of 10.5%
and 16.4% respectively (p=0. 5375)
402
Table I. Clinical characteristics of patients by treatment option
Clinical characteristics Treatment schedule
IFW ITW
No of patients 57 61
Male/female 32/25 33/28
Median age (years) 49 47
Karnofsky’s performance status (KPS)
60% 32 (56%) 30 (49%)
more then 60% 25 (44%) 31 (51%)
Neurological performance status (NPS)
1 24 (39%) 16 (28%)
2 28 (46%) 33 (58%)
3 9 (15%) 8 (14%)
Tumor location
frontal 20 (35%) 23 (38%)
temporal 19 (33%) 23 (38%)
parietal 18 (32%) 14 (23%)
occipital – 1 (1%)
Table II. Therapeutic characteristics by treatment option
Characteristics Treatment schedule
IFW ITW
Surgery
total resection 11 (19%) 16 (26%)
partial resection 46 (81%) 45 (74%)
TSI
3-4 weeks 28 (49%) 29 (47%)
more then 4 weeks 29 (51%) 32 (53%)
Irradiation technique
two fields 16 (28%) 22 (36%)
three fields 41 (72%) 39 (64%)
TSI- time between surgery and first course of irradiation
Table III presents the univariate analysis of
prognostic factors.
Multivariate analysis showed that only age and NPS
correlated with survival. Patients under 40 years of age
and patients with NPS score 1 had the best prognosis
(Table IV).
The probability of survival according to patient age
and NPS has been presented on Figures 2 and 3.
Discussion
Hypofractionation refers to the use of a fewer number
of large size radiation fractions. As radiotherapy is not
curative and survival is short, a hypofractionated schedule
that would provide the same survival as a conventionally
fractionated one, and with equivalent toxicity, would be
useful in the management of patients with glioblastoma
[8]. Hypofractionated regimens have been proposed in
many centers, and the following radiation schedules were
used: 30 Gy in 6 fractions, 30 Gy in 10 fractions, 36 Gy in
12 fractions, 37.5 Gy in 15 fractions, and 42 Gy in 14
403
Figure 1. Actuarial survival of 57 patients treated with IFW (solid line) and 61 patients treated
with ITW (dashed line)
Table III. Univariate analysis of prognostic factors
Factor No of Two-year Log-rank test
patients OS (%) p-value
Age (years)
40 and under 35 27
over 40 83 2.6 0.0000
Gender
male 65 12.9
female 53 14.2 0.2933
KPS
60% 62 8.1
more then 60% 56 19.6 0.0032
NPS
1 40 22.7
2 61 10.5
3 17 - 0.0002
Tumor location
frontal 43 16.1
temporal 42 14.5
parietal 32 6.2 0.6223
occipital 1 -
Surgery
total resection 27 16.8
partial resection 91 12.7 0.2389
TSI
3-4 weeks 57 13.1
more then 4 weeks 61 14.2 0.9264
Irradiation technique
two fields 38 18.4
three fields 80 11.2 0.7931
Table IV. Definitive Cox’s model
Factor Relative risk p-value
Age (years
40 and less 1.00
more then 40 2.85 0.0000
NPS
1 1.00
2 1.28
3 2.55 0.0045
fractions. The number of patients treated in these series
ranged from 21 to 219. Age criteria varied from 38 to 70
years, KPS was generally 50 and less, median survival
ranged from 4 to 8 months [9, 10-14]. Slotman et al.
presented a prospective, non-randomized study of 30
patients treated with a hypofractionated radiation
schedule (42 Gy in 14 fractions). Median survival time
(MST) was 36 weeks and age, KPS, and extent of surgery
correlated strongly with survival. Patients with three
favorable prognostic factors (age less then 50 yrs., KPS 80-
100, and 75% or more of the tumor mass excised had the
best prognosis (MST: 50 weeks) [11]. Bauman et al.
cautioned, that elderly patients with a higher pretreatment
KPS (above 50) may benefit from a higher dose radio-
therapy regimen [9].
In our material the patient characteristics did not
differ from those published recently by other Polish
oncological institutions [15, 16]. Glioblastomas were more
frequent in men, the median age of patients was over 55
years, frontal and temporal lobe localization was observed
in 35% of cases, and less than 25% of patients underwent
total tumor resection.
In our series of 118 adult patients with glioblastoma
we found that, in uinivariate analysis, patient age, KPS
and NPS correlated with survival. To establish the relative
value of the known prognostic factors we performed
a multivariate analysis. If all variables (age, gender, KPS,
NPS of patients, tumor location, surgery, TSI, irradiation
techniques) were entered into the model with a stepwise
forward multiple regression, only age and NPS were
found to influence the prognosis of survival. We have
proven, that the youngest quartile, up to 40 years of age,
achieved a 2-year OS of 27%, while older patients had
markedly poorer survival, with a 2-year OS of 2.6%.
Patient age is widely recognized as a patient-related
prognostic factor. Several other studies had demonstrated
better results in younger patients. The cut-off point seems
to lie somewhere between 40 and 45 years of age [1, 2, 8,
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Figure 2. Actuarial survival according to patient age
Figure 3. Actuarial survival according to the NPS
9, 11, 17]. An interesting observation was made by K´pka
et al. In their study age did not achieve statistical
significance when the cut-off point value of age was set at
50 years. Using this approach to data assessment, there
was no difference in one year-survival, but at two years,
patients below 50 years of age had a more favorable
treatment outcome [15]. In study from the Âwi´tokrzyskie
Cancer Center in Kielce, patient age was assessed to be
statistically significant for both overall and progression-
free survival [16]. Lutterbach et al. have selected an age-
range of 60-65 years to define the two different prognostic
subgroups for survival, with a significant worsening in the
case of older patients [18].
In our material there was no statistically significant
difference in survival between patients who underwent
total resection as compared to partial resection. 2-year OS
for the former group was 16.7%, as compared to 12.8% in
the latter group. In a study from the Maria Sklodowska-
Curie Memorial Cancer Center in Warsaw, the extent of
resection was the best predictor of survival. The MST
after total tumor removal was twice a long as that after
biopsies and partial or subtotal resections, i.e. 12 vs. 6
months, respectively [15]. The role of surgical resection in
the management of patients with malignant gliomas
remains controversial, despite the prospective randomized
studies of BTSG and other trials, demonstrating
a significant impact of the extent of surgery on median
survival, even when adjusted for age, histology and
performance status [19]. Simpson et al. have shown
a positive correlation of survival time and extent of
resection, and conclude that a maximal surgical resection
consistent with acceptable preservation of neurological
function should be an integral part of multimodal
management of patients with malignant gliomas [20].
Wood et al. have confirmed a negative correlation
between the size of the residual tumor and survival [21].
Some reports did not find any correlation between the
extent of surgery and survival [1, 2, 16]. Basing upon our
own experience we think that the impact of the extent of
surgery is difficult to ascertain due to the inadequate
terminology used in surgical reports, which vary from
surgeon to surgeon.
Tumor location had no influence on survival time. In
patients with frontal, temporal and parietal sites the 2-
year OS was 16%, 14.6% and 6.2% respectively. The
relevance of tumor location is unclear, some authors have
observed better outcomes in patients with frontal lobe
tumors, whereas others did not [2, 17, 22]. One could
speculate, that complete tumor resection is easier to
achieve in case of frontal localisation [20].
Gender did not significantly affect survival, as has
been also reported by other authors [1, 2, 17].
We have not proven the prognostic value of KPS on
patient outcome, which contradicts the data of Ducci, i.e.
that the KPS is one of the most significant prognostic
factors [23]. Sachsenheimer et al. evaluated the KPS as
regarding survival and found that 75% of patients
maintained a KPS of 70 for approximately 1 year; and
then presented with a rapid decline in function
immediately before death. Consequently, KPS used alone
may not adequately reflect the effects of both tumor
presence and treatment on OS [24].
The most direct measurement of the effect of the
tumor on the brain is neurological impairment. Thus, to
evaluate neurological function we applied the
EORTC/MRC neurological deficit score and we have
observed a significant difference between the prognosis of
patients with grade 1, 2, and 3 NPS. The corresponding 2-
year OS was 22.7, 10.1, and 0%, respectively. Our findings
are consistent with the observations of Florek et al. who
noted a 2-year OS of 10% and 21%, respectively, for 1-2
and 3-4 NPS values [16].
While designing this study we believed that
a hypofractionated course of irradiation will not confer
any true survival advantage for glioblastoma patients; our
main aim was to achieve equivalent survival with a shorter
radiation scheme (ITW). The efficacy of the two different
hypofractionated regimens administered to our patients
provided, approximately, the same and, unfortunately,
poorly results. We, therefore, conclude that patients with
glioblastoma treated with hypofractionated regimens do
not have a worse outcome than patients irradiated with
a conventional regimen. From the social and financial
standpoint, this can be an interesting finding.
Concomitant chemoradiotherapy (the addition of
temozolomide to conventional irradiation) is associated
with some new successes in the treatment of glioblastoma
[25, 26]. Maybe non-conventional fractionated radio-
therapy will be considered as a part of forthcoming trials
in which temozolomide or other alkylating agents will be
used.
Conclusions
Both our hypofractionated regimens were well tolerated
and provided similar results.
Patient age and their neurological performance
status were the most important prognostic factors.
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